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Objective: Melanoma differentiation-associated gene 7 is a novel tumor suppressor
gene that induces apoptosis in lung cancer cells when delivered by adenoviral gene
transfer as Ad-mda7. The mechanisms of action are not well defined but may involve
release of cytochrome c from the mitochondria with subsequent caspase activation.
Methods: The lung cancer cell lines A549 and H1299 were transduced with
Ad-mda7, adenovirus containing the gene for p53 (Ad-p53), and control adenoviral
luciferase vectors. Staurosporine was used as a positive control to induce cyto-
chrome c release through mitochondrial permeability transition-dependent pores,
whereas cyclosporine (INN: ciclosporin) was used to specifically inhibit these
mitochondrial permeability transition-dependent pores. Apoptosis was evaluated with
fluorescence-activated cell sorting analysis of subdiploid populations and mitochondrial
membrane potential changes with tetramethylrhodamine ethylester perchlorate.
Results: Melanoma differentiation-associated gene 7, transduced by Ad-mda7 into
H1299 and A549 lung cancer cells, resulted in sharp increases in cytosolic cyto-
chrome c levels followed by induction of apoptosis and cellular death. The release
of cytochrome c from the mitochondria occurred without changes in the mitochon-
drial membrane potential. Unlike staurosporine treatment, transduction with Ad-p53
and Ad-mda7 caused releases of cytochrome c and apoptosis that were not blocked
by cyclosporine, suggesting a mitochondrial permeability transition pore-indepen-
dent pathway.
Conclusions: Ad-mda7 induces apoptosis in lung cancer cells through mitochondrial
cytochrome c release in a process that is not dependent on mitochondrial membrane
potential changes and occurs through mitochondrial permeability transition-inde-
pendent pores. This unique mechanism of action may allow treatment of patients
with lung cancer resistant to mitochondrial permeability transition-dependent cell
death processes.
Locoregionally advanced lung cancer remains a significant clinicalproblem with few therapeutic options. Conventional therapy withsurgery, chemotherapy, or radiotherapy has been ineffective in ob-taining a cure for most patients.1,2 The advent of gene therapy offersa novel mode of therapy to treat lung cancer through the transfer offunctional genes. Phase I and II clinical trials in lung cancer have
demonstrated the feasibility of transferring wild-type p53 with adenoviral vectors
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(Ad-p53) to induce apoptosis and cellular death.3-5 Unfor-
tunately, some patients are resistant to Ad-p53 gene transfer
because of molecular changes in downstream mediators of
apoptosis. Thus there is a need for other genes to be iden-
tified that can treat patients with lung cancer resistant to p53
gene transfer. Melanoma differentiation-associated gene 7
(mda-7) is a novel tumor suppressor gene that was first
identified by subtraction hybridization of a melanoma cell
line treated with interferon  and mezerin.6 Adenoviral
transfer of mda-7 (Ad-mda7) induces apoptosis in a wide
range of cancer cells, including p53-sensitive (H1299) and
p53-resistant (A549) lung cancer cells.7 The mechanism by
which Ad-mda7 induces apoptosis, however, is not well
defined.
Because the mitochondrial release of cytochrome c is a
critical step in the cell’s commitment to apoptosis and
cellular death, we focused on the effects of Ad-mda7 on the
mitochondria and compared them with those of other known
apoptotic inducers. One class of proapoptotic stimuli (such
as p53, Bax, Bak, and staurosporine) are dependent on
mitochondrial membrane potential (MMP) changes to in-
duce opening of mitochondrial permeability transition
(MPT)-dependent pores, which then release cytochrome c
and other apoptogenic factors.8-10 MPT-dependent pores are
multiprotein complexes that span the inner and outer mito-
chondrial membranes and allow the release of cytochrome c
into the cytosol from the intramitochondrial space after
MMP changes. In this class of apoptosis-inducing agents,
the release of cytochrome c through MPT-dependent pores
can be blocked by cyclosporine (INN: ciclosporin) and
bongkrekic acid, inhibiting the onset of apoptosis and cel-
lular death. Other apoptosis-inducing agents, such as Bid,
however, may not be dependent on MMP changes to induce
cytochrome c release and appear to be able to release
cytochrome c through MPT-independent pores that are not
blocked by cyclosporine or bongkrekic acid .11,12
In this study we found that Ad-mda7 induced cyto-
chrome c release through MPT-independent pores that were
not blocked by cyclosporine. This unique mechanism of
action occurred in both p53-sensitive (H1299) and p53-
resistant (A549) cell lines, which provides some insight into
molecular differences of action between Ad-mda7 and Ad-
p53. The ability of Ad-mda7 to induce cytochrome c release
through MPT-independent pores may allow a novel means
of treating patients with lung cancer resistant to Ad-p53 and
other MPT-dependent cell death processes.
Material and Methods
Cell Lines and Immunoblot Assay
A549 (p53 resistant) and H1299 (p53 sensitive) human lung cancer
cell lines were obtained from the American Type Culture Collec-
tion (American Type Culture Collection, Manassas, Va). All cells
were maintained in Roswell Park Memorial Institute medium 1640
supplemented with 10% fetal bovine serum, 10-mmol/L glu-
tamine, 100-U/mL penicillin, and 100-g/mL streptomycin (Life
Technologies, Inc, Rockville, Md) in a 5% carbon dioxide atmo-
sphere at 37°C.
Immunoblot assays were performed with total cell lysates,
which were prepared by lysing cell monolayers in plates with
sodium dodecylsulfate (SDS) polyacrylamide gel electrophoresis
(PAGE). Each lane was loaded with 5 g of cell lysate protein, as
determined by BCA protein assay (Pierce Chemical Company,
Rockford, Ill). Subsequently, proteins were separated under reduc-
ing conditions by SDS-PAGE. After electrophoresis at 20 mA for
2 hours, the proteins in the gels were transferred to Hybond-ECL
membranes (Amersham Pharmacia Biotech, Inc, Piscataway, NJ).
Then the membranes were blocked with 1% dry milk and 0.1%
polysorbate 20 (Sigma, St Louis, Mo) and incubated with primary
antibodies. The membranes were then incubated with secondary
antibody conjugated with horseradish peroxidase (Amersham).
The membranes were developed according to the Amersham ECL
protocol. Relative quantities of protein were determined with a
densitometer (Molecular Dynamics, Inc, Sunnyvale, Calif). Anti-
bodies to the following were used: Bax, Bak, Bcl-2, Fas, FasL, and
-actin (Santa Cruz Biotechnology, Inc, Santa Cruz, Calif); cyto-
chrome c (BD PharMingen, San Diego, Calif); and FADD, tumor
necrosis factor (TNF) receptor 1, TNF-, and TRADD (BioSource
International, Inc, Camarillo, Calif).
Adenovirus Production and Transduction
Construction methods of the adenovirus vectors Ad-mda7, Ad-
p53, Ad-LacZ, and Ad-luc (luciferase) have been reported previ-
ously elsewhere.13 The transduction efficiencies of the cell lines
were determined with Ad-LacZ. Subsequent experiments used
viral titers needed to transduce at least 70% of the cells.
Apoptosis and Cellular Viability Assays
We measured apoptotic cells by propidium iodide staining and
fluorescence-activated cell sorting (FACS) analysis. Cells were
harvested, reduced to pellets by centrifugation, and resuspended in
phosphate-buffered saline solution (PBS) containing 50-g/mL
propidium iodide, 0.1% Triton X-100 (The Dow Chemical Com-
pany, Midland, Mich), and 0.1% sodium citrate. Samples were
stored at 4°C for 16 hours and vortex mixed before FACS analysis
(FACScan, FL-3 channel; BD Immunocytometry Systems, San
Jose, Calif). Cells were grown in 96-well plates in 100 L volume/
well. On day 1, cells were transduced with Ad-mda7, Ad-p53, or
control vectors. On day 2, the cells were incubated with the
tetrazolium salt XTT for 4 to 24 hours according to the Roche
protocol (Roche Diagnostics GmbH, Mannheim, Germany). Via-
bility was assessed spectrophotometrically on an enzyme-linked
immunosorbent assay plate reader.
MMP Measurements
The potential-sensitive fluorochrome tetramethylrhodamine ethyl-
ester perchlorate (TMRE; Molecular Probes, Inc, Eugene, Ore)
was used to measure MMP changes. Cells were incubated with
25-nmol/L TMRE for 30 minutes at 37°C in the dark, washed in
PBS, and analyzed by FACS on the FL-2 channel (FACScan).14
Cytochrome c Release Measurements
Release of cytochrome c from mitochondria was measured by
immunoblotting. Cells were harvested by centrifugation and gently
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lysed for 5 minutes in an ice-cold buffer containing 25-mmol/L
tris(hydroxymethyl)aminomethane and 5-mmol/L magnesium
chloride, pH 7.4. Lysates were centrifuged for 5 minutes at
16,000g, supernatants were mixed with 1 Laemmli reducing
SDS-PAGE sample buffer, and extracts from equal numbers of
cells (10-20  106) were resolved by 15% SDS-PAGE. Polypep-
tides were transferred to nitrocellulose membranes (0.2 mol/L;
Schleicher & Schuell Inc, Keene, NH), and cytochrome c was
detected by immunoblotting with the monoclonal antibody clone
7H8.2C12 (BD PharMingen).
Statistical Analysis
The data reported in the figures represent the means of three
independent experiments with SDs. Analysis of variance and the
two-tailed Student t test were used for statistical analysis of mul-
tiple groups and pairwise comparisons, respectively.
Results
Ad-mda7 Induction of Apoptosis and Cytochrome c
Release from Mitochondria
Cellular viability was assessed with the XTT assay. Trans-
duction of both the p53-resistant (A549) and p53-sensitive
(H1299, data not shown) lung cancer cell lines resulted in
marked decrease in cellular viability 48 to 72 hours after
infection (Figure 1, A). Induction of apoptosis induction was
evaluated by flow cytometric analysis of subdiploid popu-
lations. Both A549 and H1299 (data not shown) lung cancer
cells demonstrated apoptosis induction 48 to 96 hours after
Ad-mda7 transduction. No apoptosis was seen in Ad-luc-
treated or PBS-treated cells (Figure 1, B). Transduction of
both A549 and H1299 lung cancer cell lines with Ad-mda7
resulted in cytochrome c release into the cytosol 48 hours
after treatment. This corresponded to the onset of apoptosis
and demonstrated involvement of the mitochondria in the
apoptotic cascade (Figure 2). Only Ad-mda7-transduced
cells demonstrated mda-7 protein expression by Western
blotting (data not shown).
Ad-mda7s Effects on MMP Changes and Apoptosis
Disruption of the MMP is an essential event in the devel-
opment of apoptosis after treatment with MPT-dependent
apoptotic agents. Staurosporine was used as a positive con-
trol for MPT-dependent apoptotic agents. In H1299 cells,
both Ad-p53 and staurosporine induced MMP changes and
apoptosis, presumably through release of cytochrome c
through MPT-dependent pores. Both the MMP changes and
apoptosis were inhibited by cyclosporine, which selectively
blocks MPT-dependent pores (Figures 3, A, and 4, A).
Ad-mda7, however, did not induce MMP changes but was
still able to induce apoptosis that was not inhibited by
cyclosporine. In A549 cells, Ad-p53 was unable to induce
Figure 2. Kinetics of cytochrome c (Cyt C) release induced by
Ad-mda7. Cytosolic extracts from A549 (A) and H1299 (B) cells
were prepared for analysis of cytochrome c release, and DNA
fragmentation was also assessed by propidium staining and flow
cytometry.
Figure 1. Adenovirally mediated overexpression of mda-7 suppresses proliferation and induces cell death in lung
cancer cells. A, Cell viability was determined with XTT assay in A549 cells after treatment with PBS, Ad-luc (2500
vp), or Ad-mda7 (2500 vp). B, Percentage of cell death. Cells were analyzed by flow cytometry after transduction.
Triplicate experiments were performed for each cell line. Bar heights represent mean; error bars represent SD.
Asterisk indicates P < .05.
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apoptosis or MPT changes (Figures 3, B, and 4, B). We used
staurosporine as a positive control because it induces MMP
changes and apoptosis in H1299 and A549 cells, both of
which are blocked by cyclosporine, presumably because of
inhibition of MPT-dependent pores. Interestingly, Ad-mda7
does induce MMP changes, but these changes are not re-
versed by cyclosporine. Additionally, cyclosporine is un-
able to inhibit Ad-mda7-induced apoptosis. Taken to-
gether, these data suggest that Ad-mda7-induced
apoptosis and cytochrome c release may occur through
MPT-independent pores that are not blocked by cyclo-
sporine.
Figure 3. Effect of Ad-mda7 on MMP. Measurement of MMP after treatment with Ad-mda7, Ad-p53, and stauro-
sporine (ST, 1 mol/L). Where indicated, cells were pretreated with cyclosporine (CsA, 10 mol/L). H1299 (A) and
A549 (B) cells were stained with potential-sensitive dye TMRE, and fluorescence was assessed by flow cytometry.
Triplicate experiments were performed for each cell line. Bar heights represent mean; error bars represent SD.
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Ad-mda7 Upward Regulation of Extrinsic Pathway in
A549 Cells
To determine whether Ad-mda7 activated the mitochondria
through upward regulation of the Bcl-2 family of genes or
the death receptor pathway in A549 cells, Ad-mda7-treated
cells (A549) were assessed by immunoblot assay for
changes in Bak, Bax, Bcl-2, TNF-, TNF receptor 1,
TRADD, FasL, Fas, and FADD expressions (Figure 5). No
differences in Bcl-2 family members were seen in A549
cells other than Bid activation, as previously reported,6 and
significant upward regulation of FasL (Figure 5). Although
Fas receptor function was not evaluated in A549 cells, we
did observe caspase 8 activation and apoptosis inhibition by
caspase 8 inhibitors (data not shown), which suggests up-
ward regulation of the extrinsic death receptor pathway in
A549 cells after Ad-mda7 transduction.
Discussion
Gene therapy offers the opportunity of a new modality of
therapy for locoregionally advanced lung cancer. In a re-
cently completed phase II trial that combined Ad-p53 with
radiation therapy, more than 60% of the tumors demon-
strated no viable tumor in core biopsy specimens 3 months
after treatment.4,5 It is clear, however, that not all patients
have a response to Ad-p53, and some with an initial re-
sponse to Ad-p53 ultimately have disease progression de-
spite continued treatment. Additionally, preclinical experi-
ence with lung cancer cell lines has demonstrated p53
Figure 4. Cyclosporine (CsA) does not prevent loss of MMP. H1299 (A) and A549 (B) cells were treated with
Ad-mda7, Ad-p53, and staurosporine (ST, 1 mol/L). Where indicated, cells were pretreated with cyclosporine
(CsA, 10 mol/L). After times indicated, cells were lysed, and MPP was determined with fluorescent dye TMRE as
described in Material and Methods section.
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resistance in a number of cell lines, including the A549
human lung cancer cell line.15 The reasons for this resis-
tance have not been delineated. We therefore evaluated the
effectiveness of adenoviral transfer of the novel tumor sup-
pressor gene mda-7 and sought to determine the molecular
mechanisms of action differentiating this gene from other
classic apoptosis-inducing agents.
In this study we chose to focus on the mitochondria,
because many investigators have suggested that mitochon-
drial activation and cytochrome c release are the critical
steps in cellular commitment to apoptosis.16-18 Several pro-
apoptotic genes, including Bax, Bak, and p53, are believed
to induce MMP changes that open MPT-dependent pores
that allow the release of cytochrome c and formation of an
apoptosome with cytochrome c, APAF-1, and caspase 9
(Figure 6).8-10 This apoptosome activates caspases 3, 6, and
7, leading to the executioner phase of apoptosis with cleav-
age of a variety of cellular substrates, including PARP, DFF
45, and gelsolin. These classic proapoptotic agents can be
inhibited by cyclosporine or bongkrekic acid, which block
the MPT-dependent pores, preventing MMP changes and
cytochrome c release.9,10 Previous studies have demon-
strated that cytochrome c is not released after Ad-p53 treat-
ment in resistant A549 cells, suggesting a possible defect at
the mitochondrial level of action.15 Our finding of cyto-
chrome c release after Ad-mda7 treatment is interesting
because it suggests that Ad-mda7 is able to induce apoptosis
through cytochrome c release despite Ad-p53 resistance.
This ability to induce killing in p53-resistant cells has
potential therapeutic implications, because Ad-mda7 ap-
pears to act through a unique mechanism.
Our findings suggest that Ad-mda7 induces cytochrome
c release from the mitochondria into the cytosol through
MPT-independent pores, because cyclosporine is unable to
inhibit apoptosis or cytochrome c release after Ad-mda7
transduction (Figure 4, A and B) but is fully capable of
blocking the classic MPT-dependent apoptosis agents stau-
rosporine and Ad-p53. How Ad-mda7 induces apoptosis
through MPT-independent pores is not clear, but the induc-
tion may be due in part to activation of the extrinsic death
receptor pathway. It is important to remember that this may
be cell-line specific (A549 cells), because other authors
have demonstrated Ad-mda7-induced apoptosis in other cell
lines in the absence of Bid cleavage.13 In A549 cells we saw
no changes in levels of Bax or Bak, which are known to act
by releasing cytochrome c through MPT-dependent pores
inhibitable by cyclosporine or bongkrekic acid.10 We noted,
however, increases in FasL, which can act through the
extrinsic death receptor pathway by activating caspase 8,
leading to Bid cleavage and mitochondrial activation (Fig-
ure 6). This is consistent with our previously reported ob-
servation of caspase 8 activation and Bid cleavage after
Ad-mda7 transduction of A549 lung cancer cells, mediated
in part through upward regulation of the interferon-induc-
ible double-stranded RNA protein kinase and other protein
intermediaries, although in a longer time course (48 to 96
hours) than such direct apoptosis agents such as Ad-Bak.6
Several authors have observed that Bid, unlike Bak or Bax,
induces cytochrome c release through a pathway indepen-
dent of MPT-dependent pores11,12 perhaps by oligomerizing
Bak or Bax into their own MPT-independent pores in the
outer mitochondrial membrane.19
We have previously reported that adenovirally mediated
overexpression of Bak or Bax could induce apoptosis in
p53-sensitive and p53-resistant lung cancer cells, suggest-
ing that other MPT-dependent apoptotic agents are able to
induce a killing effect in A549 cells.15,20 These observations
suggest that the defect in Ad-p53 killing of A549 cells may
be above the mitochondrial checkpoint, because staurospor-
ine, Ad-Bax, and Ad-Bak induce mitochondrial activation
and apoptosis, presumably through functional MPT-depen-
dent pathways. From a therapeutic standpoint Ad-mda7 has
a significant advantage over Ad-Bak or Ad-Bax, because
both of the latter vectors also induce killing of normal cells,
whereas Ad-mda7 spares normal cells. Ad-mda7 is there-
fore able to kill p53-resistant A549 cells in a tumor-selec-
tive fashion, without the toxicity associated with Ad-Bax or
Ad-Bak.
Figure 5. Ad-mda7 induces FasL. A, Western blot analysis of expressions of Bax, Bak, Bcl-2, TNF-, TNF receptor
1 (TNF-R1), TRADD, FasL, Fas, and FADD in A549 cell lysates 48 hours after treatment with PBS, Ad-luc, or Ad-mda7.
Expression level of actin was used as control.
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In summary, we have shown that adenovirally mediated
overexpression of mda-7 leads to rapid induction of apo-
ptosis in p53-resistant and p53-sensitive lung cancer cells.
Ad-mda7s mitochondrial mechanism appears to act
through MPT-independent pore release of cytochrome c,
with subsequent activation of executioner caspases and cel-
lular death. The upward regulation of FasL, caspase 8
activation and Bid cleavage, suggests that Ad-mda7 may be
acting preferentially through the extrinsic death receptor
pathway in A549 cells, with subsequent mitochondrial ac-
tivation and MPT-independent cytochrome c release. This
unique mechanism of action may provide a novel means of
treating patients with lung cancer resistant to p53 and other
MPT-dependent cell death processes.
We thank Debbie Smith for her assistance in the preparation of
the manuscript.
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Discussion
Dr David R. Jones (Charlottesville, Va). I have a question
regarding other strategies to more completely evaluate your pro-
posed mechanism of action. Did you consider doing a cotransfec-
tion with a dominant-negative FADD or the treating the cells with
CrmA to see whether this indeed would block the caspase 8
pathway? If so, did this subsequently affect your mitochondrial
permeability?
Dr Swisher. That is a very interesting question, and to answer
that, we are getting fibroblasts that are FADD deficient. We have
used caspase 8 inhibitors and noted inhibition of caspase 8 activity
and apoptosis in the A549 cells. It is important to keep in mind that
upward regulation of the extrinsic death receptor pathway may be
cell specific. Adenovirally transfected mda-7 can work in a variety
of different ways in a variety of different cells. In the cell that I
showed you, it went through the extrinsic death receptor pathway,
but in other cells we can see upward regulation of Bak and Bcl-2.
The common theme appears to be a little bit further down, at the
mitochondrial level of action.
Dr Dao M. Nguyen (Bethesda, Md). These are intriguing
findings, and I have a few questions. First, going back to the
upward regulation of the Fas-Fas ligand pathway, have you tried to
block it with blocking antibodies to see whether you can take away
the apoptosis-inducing effect of this mda-7? The second question
regards the time course of the study of the membrane depolariza-
tion. There are two models of mitochondrial membrane depolar-
ization that are described and adopted in the literature. In one
model, mitochondrial damage is mediated by opening of the volt-
age-dependent anion channels, leading to translocation of many
apoptosis-inducing factors, including cytochrome c. In the other
model, mitochondrial damage occurs after caspase activation. Ac-
cording to the second model, cytochrome c release occurs early, is
not necessarily connected to mitochondrial depolarization, and is
mediated by Bax/Bcl-2 in response to an apoptosis signal. Mito-
chondrial depolarization occurs only in the presence of complete
caspase activation. I just wondered whether if you waited long
enough beyond the 72-hour time point, you might start seeing the
depolarization, which is a secondary phenomenon resulting from
activation of caspases and not secondary to cytochrome c release.
Dr Swisher. As your question points out, this is a controversial
area. I am not going to attempt to answer all the many different
hypotheses that have been generated. The only thing that our data
clearly showed was that cytochrome c was released from the
mitochondria through pores that were not inhibitable by cyclospor-
ine and were not always dependent on mitochondrial membrane
changes. But there is, as you have mentioned, extensive discussion
in the literature about mitochondrial membrane depolarization.
Does everything have to go through those MMP-dependent pores?
My own feeling is that there are probably multiple pores, both
MMP dependent and independent.
With regard to the Fas ligand question, we have been able to
induce apoptosis in these cells with Fas-inducing antibody. We
have not tried yet with blocking antibodies, but that would be a
good experiment.
Dr Peter K. Kim (Pittsburgh, Pa). I believe that A549 cells
have a defect in expressing Fas on the surface, and I wonder
whether your mda-7 is also upwardly regulating expression of Fas
on the surface. Have you looked by immunohistochemical meth-
ods to see whether that is occurring?
Dr Swisher. At a Western blotting level, we saw upward
regulation of Fas ligand, and it is purely speculative what is going
on at the receptor level. But we do not have evidence, at least in
Western blotting, of upward regulation of the actual Fas receptor.
Dr Kim. So there is Fas protein in the cells, but even though
the total levels do not change, maybe you are getting more ex-
pression of Fas on the cell surface that is then interacting with the
Fas ligand to kill the cells?
Dr Swisher. Right, and there is a variety of other potential
things too. The mda-7 may be acting on the inside of the receptor,
and it may have nothing to do with that upward regulation of Fas
ligand. We do see caspase 8 activation in the A549 cells, and we
do see Bid cleavage, which definitely means that the pathway is
activated at least in A549 cells. There are reports in the literature
that Bid can interact with Bax on the cell surface and allow
cytochrome c release without MMP changes, so this may be the
mechanism that is working with the A549 cells that we are eval-
uating.
Dr John H. Stewart (Bethesda, Md). You showed that Bid was
cleaved; however, the total protein levels of Bax remained the
same. Are you interested in the future at looking at conformational
changes in Bax and to see whether your adenovirus is involved in
that pathway of inducing cytochrome c release?
Dr Swisher. That is an interesting question, because cell lines
differ in the response to Ad-mda7. We have looked at Ad-mda7
before in other cell lines, and we have seen upward regulation of
Bax and Bak, but in certain cell lines mda-7 appears to preferen-
tially work through the extrinsic death receptor. Whether that’s
cell-type specific we do not know for sure. But in this one cell line
it did appear to be mostly through the extrinsic pathway and not
through Bcl-2 and Bax and Bak pathway.
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